Thus, MEK inhibitors’ monotherapy or combination with other targeted drugs harboring MAPK pathway become a promising strategy for NSCLC patients with B-Raf proto-oncogene (BRAF) or Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.